GLSI vs. SCPH, CAPR, IVA, MCRB, GOSS, TELO, OGI, ALIM, PRQR, and SKYE
Should you be buying Greenwich LifeSciences stock or one of its competitors? The main competitors of Greenwich LifeSciences include scPharmaceuticals (SCPH), Capricor Therapeutics (CAPR), Inventiva (IVA), Seres Therapeutics (MCRB), Gossamer Bio (GOSS), Telomir Pharmaceuticals (TELO), Organigram (OGI), Alimera Sciences (ALIM), ProQR Therapeutics (PRQR), and Skye Bioscience (SKYE). These companies are all part of the "pharmaceutical preparations" industry.
scPharmaceuticals (NASDAQ:SCPH) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, community ranking, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.
In the previous week, scPharmaceuticals had 37 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 38 mentions for scPharmaceuticals and 1 mentions for Greenwich LifeSciences. scPharmaceuticals' average media sentiment score of 0.59 beat Greenwich LifeSciences' score of 0.23 indicating that Greenwich LifeSciences is being referred to more favorably in the news media.
Greenwich LifeSciences has lower revenue, but higher earnings than scPharmaceuticals. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than scPharmaceuticals, indicating that it is currently the more affordable of the two stocks.
scPharmaceuticals has a beta of 0.09, meaning that its stock price is 91% less volatile than the S&P 500. Comparatively, Greenwich LifeSciences has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500.
89.5% of scPharmaceuticals shares are owned by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are owned by institutional investors. 4.7% of scPharmaceuticals shares are owned by company insiders. Comparatively, 52.9% of Greenwich LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
scPharmaceuticals currently has a consensus target price of $19.00, suggesting a potential upside of 300.00%. Greenwich LifeSciences has a consensus target price of $36.00, suggesting a potential upside of 157.51%. Given Greenwich LifeSciences' higher possible upside, equities research analysts plainly believe scPharmaceuticals is more favorable than Greenwich LifeSciences.
Greenwich LifeSciences has a net margin of 0.00% compared to Greenwich LifeSciences' net margin of -327.29%. scPharmaceuticals' return on equity of -93.88% beat Greenwich LifeSciences' return on equity.
scPharmaceuticals received 152 more outperform votes than Greenwich LifeSciences when rated by MarketBeat users. Likewise, 66.24% of users gave scPharmaceuticals an outperform vote while only 33.33% of users gave Greenwich LifeSciences an outperform vote.
Summary
scPharmaceuticals beats Greenwich LifeSciences on 9 of the 16 factors compared between the two stocks.
Get Greenwich LifeSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLSI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GLSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Greenwich LifeSciences Competitors List
Related Companies and Tools
